AbbVie (ABBV) announced plans to launch ELAHERE in the U.K. at a list price equal to the U.S. AbbVie is in discussions with the National Institute for Health and Care Excellence to ensure that ELAHERE is valued fairly. The company noted that the value given to ELAHERE will determine the ability to launch in the U.K.
The European Commission granted approval of ELAHERE in November 2024 and was granted full FDA approval in the U.S. in March 2024. In July, the Medicines and Healthcare products Regulatory Agency approved ELAHERE.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.